Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Appoints Cory J. Dunn Senior Vice President of Commercial Operations
SAN DIEGO , Feb. 14, 2020 /PRNewswire/ --  Biocept, Inc.  (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the promotion of Cory J.
View HTML
Toggle Summary Biocept Enters into Laboratory Services Agreement with California-Based Independent Physician Association
Large independent physician association serving California now offers access to Biocept's Target Selector™ liquid biopsy testing for the management of patients diagnosed with cancer SAN DIEGO , Feb. 10, 2020 /PRNewswire/ -- Biocept, Inc.  (Nasdaq: BIOC), a leading commercial provider of liquid
View HTML
Toggle Summary Biocept to Present at the 22nd Annual BIO CEO & Investor Conference
SAN DIEGO , Feb. 4, 2020 /PRNewswire/ -- Biocept, Inc.  (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael W.
View HTML
Toggle Summary Biocept Announces Validation and Availability of its Liquid Biopsy Platform for the Detection of Actionable Cancer Biomarkers in Cerebrospinal Fluid
Biocept's patented Target Selector™ technology enables new specimen type--cerebrospinal fluid (CSF)--to identify biomarkers that can aid physicians in making treatment decisions SAN DIEGO , Jan. 14, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy
View HTML
Toggle Summary Biocept, Inc. Awarded United States Patent for the Use of Antibodies in Combination with Any Solid Surface to Detect Any Target Cell of Interest - from Any Sample Type
Biocept further expands its patent estate for capturing and detecting target cells of interest, including circulating tumor cells SAN DIEGO , Jan. 8, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular offerings designed to provide physicians with
View HTML
Toggle Summary Biocept Announces Closing of $10.0 Million Underwritten Public Offering
SAN DIEGO , Dec. 12, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy solutions, today announced that on December 11, 2019 it closed its previously announced underwritten public offering of 24,600,000 shares of its
View HTML
Toggle Summary Biocept Announces Pricing of $10.0 Million Underwritten Public Offering
SAN DIEGO , Dec. 9, 2019 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy solutions, today announced the pricing of an underwritten public offering of 24,600,000 shares of its common stock (or pre-funded warrants to
View HTML
Toggle Summary Biocept's Liquid Biopsy CTC Testing for Breast Cancer to Be Featured in Poster Presentation at the 2019 San Antonio Breast Cancer Symposium®
Target Selector™ platform demonstrates ability to accurately detect, enumerate, and interrogate circulating tumor cells (CTCs) in a cohort of over 1,500 patients, representing various clinical and treatment stages of breast cancer SAN DIEGO , Dec. 3, 2019 /PRNewswire/ --  Biocept, Inc .
View HTML
Toggle Summary Biocept Announces the Launch of its Liquid Biopsy Test to Detect TRK Biomarkers in the Blood of Patients Diagnosed with Cancer
Biocept's patented Target Selector™ test for identification of TRK proteins enables physicians to rapidly and cost-effectively identify the potential presence of NTRK fusions used to inform on treatment options SAN DIEGO , Nov. 21, 2019 /PRNewswire/ -- Biocept, Inc.
View HTML
Toggle Summary Biocept Reports Third Quarter 2019 Financial Results
- Revenues reached a record $1.5 million, up 101% over the third quarter of 2018 and up 28% over the second quarter of 2019 - The number of commercial samples received increased 66% over the third quarter of 2018 and 12% over the second quarter of 2019 - Cost of revenue reduced 23% on a per
View HTML